The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.
 
Nehal Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Mural Oncology (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
William McKean
No Relationships to Disclose
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology
Consulting or Advisory Role - Cardinal Health; Syneos Health; Telix Pharmaceuticals; Werewolf Therapeutics
 
Antonio Giordano
Consulting or Advisory Role - Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Cardiff Oncology (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Timothy Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amgen; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo Therapeutics; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity; Bloom Burton; Blueprint Medicines; Boxer Capital; BridGene Biosciences; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Chinese University of Hong Kong; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Debiopharm Group; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; FoRx Therapeutics; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Grey Wolf Therapeutics; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; Kyowa Kirin International; Lumanity; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; Prelude Therapeutics; ProLynx; Protai; Radiopharm Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; Sanofi; Schrodinger; SERVIER; Swiss Group for Clinical Cancer Research; Synnovation Therapeutics; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome Biosciences; Trevarx Biomedical; Varian Medical Systems; Veeva Systems; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boundless Bio; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); CPRIT; Cyteir (Inst); Department of Defense; EMD Serono (Inst); Exelixis; F-Star (Inst); Forbius (Inst); Genentech (Inst); Gilead Sciences; GlaxoSmithKline (Inst); Golfers Against Cancer; Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Pliant; Prelude Therapeutics; Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche; Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Synnovation Therapeutics; Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst); Zentalis
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; Amgen; AstraZeneca; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Judy Wang
Consulting or Advisory Role - Fusion Pharmaceuticals
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Alterome Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biostar Pharma (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Centessa Pharmaceuticals (Inst); Circle Pharma (Inst); Compass Therapeutics (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); DualityBio (Inst); Edgewood Oncology (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Genmab (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kumquat Biosciences (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo/Lilly (Inst); LSK Global (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MBQ Pharma (Inst); Medikine (Inst); MediLink Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); Qilu Puget Sound Biotherapeutics (Inst); Quanta Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Lab (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - NGM Biopharmaceuticals
 
Manali Bhave
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Merck; Pfizer
 
Kyaw Thein
Honoraria - Aptitude Health; Curio Science; OMNI-Oncology; Onviv Expert Network; Targeted Oncology
Consulting or Advisory Role - EMD Serono/Merck
Speakers' Bureau - Eisai
 
Jinshu Fang
Employment - Circle Pharma
Stock and Other Ownership Interests - Circle Pharma
Travel, Accommodations, Expenses - Circle Pharma
 
Eric Connor
Employment - Circle Pharma
 
Li-Fen Liu
Employment - Circle Pharma
Stock and Other Ownership Interests - Circle Pharma
Travel, Accommodations, Expenses - Circle Pharma
 
Peadar Cremin
Employment - Circle Pharma
 
Lukas Makris
Employment - Stathmi
Stock and Other Ownership Interests - Atrin Pharmaceuticals (I); Cerus (I); Immunomic Therapeutics (I); Opsidio (I); Sana Biotechnology (I)
Consulting or Advisory Role - Multiple Biotechnology companies
 
Li-Pen Tsao
Employment - Circle Pharma; Day One Biopharmaceuticals
Stock and Other Ownership Interests - Circle Pharma; Day One Biopharmaceuticals
 
Lisa Kopp
Employment - Arcus Biosciences; Circle Pharma; Covance; Day One Biopharmaceuticals
Stock and Other Ownership Interests - Arcus Biosciences; Day One Biopharmaceuticals
 
Michael Cox
Employment - Circle Pharma
Stock and Other Ownership Interests - Circle Pharma; Day One Biopharmaceuticals
Patents, Royalties, Other Intellectual Property - US patent 62/318,041 issued to Loxo Oncology. (Inst); US patent 63/251,445 issued to Day One Biopharmaceuticals, Inc. (Inst)
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); Fortress Biotech; PathomIQ
Consulting or Advisory Role - AADi; Bayer; BPGBio; Cadila Pharmaceuticals (I); Daiichi Sankyo; Genome Insight; GI Innovation; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; MOMA Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics; XY One Therapeutics
Research Funding - Adanate (Inst); ADC Therapeutics (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Day One Therapeutics (Inst); Deciphera (Inst); Elevation Oncology (Inst); Fog Pharmaceuticals (Inst); Genome & Company (Inst); Gilead Sciences (Inst); GV20 Therapeutics (Inst); Immunitas (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Nuvectis Pharma (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer